JP2024516309A5 - - Google Patents

Info

Publication number
JP2024516309A5
JP2024516309A5 JP2023568063A JP2023568063A JP2024516309A5 JP 2024516309 A5 JP2024516309 A5 JP 2024516309A5 JP 2023568063 A JP2023568063 A JP 2023568063A JP 2023568063 A JP2023568063 A JP 2023568063A JP 2024516309 A5 JP2024516309 A5 JP 2024516309A5
Authority
JP
Japan
Prior art keywords
approximately
months
immunogenic composition
composition according
strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023568063A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516309A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/027465 external-priority patent/WO2022235663A1/en
Publication of JP2024516309A publication Critical patent/JP2024516309A/ja
Publication of JP2024516309A5 publication Critical patent/JP2024516309A5/ja
Pending legal-status Critical Current

Links

JP2023568063A 2021-05-05 2022-05-03 コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法 Pending JP2024516309A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163184727P 2021-05-05 2021-05-05
US63/184,727 2021-05-05
US202163193356P 2021-05-26 2021-05-26
US63/193,356 2021-05-26
US202163255685P 2021-10-14 2021-10-14
US63/255,685 2021-10-14
US202263332537P 2022-04-19 2022-04-19
US63/332,537 2022-04-19
PCT/US2022/027465 WO2022235663A1 (en) 2021-05-05 2022-05-03 Coronavirus and influenza compositions and methods for using them

Publications (2)

Publication Number Publication Date
JP2024516309A JP2024516309A (ja) 2024-04-12
JP2024516309A5 true JP2024516309A5 (enExample) 2025-05-15

Family

ID=83901839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023568063A Pending JP2024516309A (ja) 2021-05-05 2022-05-03 コロナウイルス組成物及びインフルエンザ組成物ならびにそれらの使用方法

Country Status (11)

Country Link
US (1) US20220354944A1 (enExample)
EP (1) EP4333885A4 (enExample)
JP (1) JP2024516309A (enExample)
KR (1) KR20240024064A (enExample)
AU (1) AU2022270082A1 (enExample)
BR (1) BR112023023035A2 (enExample)
CA (1) CA3217591A1 (enExample)
IL (1) IL308180A (enExample)
MX (1) MX2023013081A (enExample)
TW (1) TW202308685A (enExample)
WO (1) WO2022235663A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2024174012A1 (pt) * 2023-02-24 2024-08-29 Instituto Butantan Composição imunogênica, uso da mesma e processo de obtenção de uma composição imunogênica combinada contra covid-19 e influenza sazonal
EP4687968A1 (en) * 2023-04-03 2026-02-11 Novavax, Inc. Coronavirus and influenza compositions and methods for using them
US20250085282A1 (en) * 2023-09-11 2025-03-13 Novavax, Inc. Method for detecting anti-sars-cov-2 spike (s) immunoglobulins
US20250144200A1 (en) * 2023-11-06 2025-05-08 Novavax, Inc. Intranasal immunogenic compositions
EP4670733A1 (en) * 2024-06-27 2025-12-31 Sanofi METHODS FOR PREPARING VIRAL PROTEINS AND THEIR USES

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2826058C (en) * 2011-02-04 2017-06-06 Zoetis Llc Compositions for canine respiratory disease complex
BR112016006122B1 (pt) * 2013-09-19 2023-11-14 Novavax, Inc COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV)
CA2996007A1 (en) * 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20230070886A1 (en) * 2020-01-27 2023-03-09 Novavax, Inc. Coronavirus vaccine formulations
US12194089B2 (en) * 2020-02-04 2025-01-14 CureVac SE Coronavirus vaccine
WO2021211749A1 (en) * 2020-04-14 2021-10-21 The Regents Of The University Of California Multi-epitope pan-coronavirus vaccine compositions
GB2596820A (en) * 2020-07-07 2022-01-12 Spicona Inc Combination vaccine
CN112546211A (zh) * 2020-10-23 2021-03-26 嘉晨西海(杭州)生物技术有限公司 基于mRNA的针对冠状病毒和流感病毒的联合疫苗及其制备方法
CN112480217B (zh) * 2020-11-30 2022-04-08 广州阿格纳生物医药制造有限公司 基于SARS-CoV-2的S抗原蛋白的疫苗和组合物
CN113185613B (zh) * 2021-04-13 2022-09-13 武汉大学 新型冠状病毒s蛋白及其亚单位疫苗

Similar Documents

Publication Publication Date Title
JP2024516309A5 (enExample)
JP2023512648A5 (enExample)
Chroboczek et al. Virus-like particles as vaccine.
JP2026026092A5 (enExample)
RU2018111760A (ru) Вакцинные композиции, характеризующиеся улучшенной стабильностью и иммуногенностью
AU2006279323B2 (en) Influenza recombinant subunit vaccine
JP5683811B2 (ja) キメラインフルエンザウイルス様粒子
KR100871021B1 (ko) 인플루엔자 백신 조성물
US20070134262A1 (en) Antigens encoded by alternative reading frames from pathogenic viruses
JP2010500399A5 (enExample)
JP2000516199A (ja) ウマの予防用ポリヌクレオチドワクチン製剤
IL305911A (en) Multifunctional nanoparticle vaccines for influenza
JP2014506562A5 (ja) 治療的免疫応答及び予防的免疫応答の両方を誘発するポリペプチド（複数可）保持ＣｙａＡ及びその使用
CN113226364A (zh) 组合物和方法
EP3474891B1 (en) Vaccine compositions comprising an attenuated mutant zika virus
JP2024545420A5 (enExample)
JP2023134738A (ja) 呼吸器疾患を治療するための方法および組成物
BRPI0811692A2 (pt) material com imunogenicidade
WO2024041612A1 (zh) 一种正痘病毒属mRNA疫苗及其制备方法和用途
JP2011524372A (ja) インフルエンザワクチン接種のための新規ペプチドアジュバント
JP2023519562A5 (enExample)
US20140199347A1 (en) Adjuvant compositions with 4-1bbl
KR20120129893A (ko) 고령자에 보호 면역을 제공하기 위한 방법 및 조성물
RU2023131792A (ru) Композиции против коронавируса и гриппа и способы их использования
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン